PT  - JOURNAL ARTICLE
AU  - Misra-Press, Anita
ED  - Schuler, Martin
TI  - LUX-Lung 5
DP  - 2015 Jun 19
TA  - MD Conference Express
PG  - 13--14
VI  - 15
IP  - 8
4099  - http://mdc.sagepub.com/content/15/8/13.short
4100  - http://mdc.sagepub.com/content/15/8/13.full
AB  - LUX-Lung 5 is the first prospective randomized, phase 3 trial to demonstrate superior progression-free survival by continuing afatinib plus paclitaxel as fourth-line treatment vs single-agent chemotherapy in patients with non–small cell lung cancer who had disease progression on chemotherapy with the combination of erlotinib plus gefitinib and with afatinib monotherapy with a manageable safety profile.